Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$0.00

(0.00%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

06:54
08/29/18
08/29
06:54
08/29/18
06:54

Germany tells drugmakers to consider no-deal Brexit risks, Reuters reports

German drugmakers including Bayer (BAYRY), Merck KGaA (MKGAY) and Boehringer Ingelheim as well as foreign suppliers like Teva (TEVA) and Roche (RHHBY) have been asked by the German government to consider the "worst-case-scenario of a hard Brexit without transition period", Reuters reports, citing meeting protocols. Germany's Federal Institute for Drugs and Medical Devices has asked industry associations to collect information on the impact of a no-deal Brexit and drug companies to examine their supply chains for any vulnerability that could result in shortages of essential drugs in that event. Reference Link

BAYRY

Bayer

$0.00

(0.00%)

MKGAY

Merck KGaA

$0.00

(0.00%)

TEVA

Teva

$23.47

0.39 (1.69%)

RHHBY

Roche

$0.00

(0.00%)

  • 10

    Sep

  • 12

    Sep

  • 16

    Sep

  • 29

    Oct

BAYRY Bayer
$0.00

(0.00%)

08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
08/21/18
BREN
08/21/18
UPGRADE
BREN
Buy
Bayer upgraded to Buy from Hold at Berenberg
08/21/18
08/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Symantec (SYMC) upgraded to Positive from Neutral at Susquehanna with analyst Anne Meisner saying that activist shareholder Starboard Value disclosing a 5.8% stake and nominating five directors to its board has introduced the potential for positive change. 2. Johnson Controls (JCI) upgraded to Buy from Hold at Argus with analyst John Eade citing the company's recent Q3 earnings beat along with the technical breakout in its stock price above the $38 resistance. 3. Discovery (DISCA) upgraded to Buy from Hold at Jefferies with analyst John Janedis saying he sees "several" opportunities that could increase Discovery's free cash flow, including stronger U.S. distribution growth, upside to realized synergies and the potential for a re-introduction of a repurchase earlier than anticipated. 4. Estee Lauder (EL) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser saying the company's fundamentals are the "strongest seen in years," with a 21% rise in FY18 operating profit and an "achievable and potentially beatable" EPS growth outlook of 9%-11% for FY19. 5. Bayer (BAYRY) upgraded to Buy from Hold at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
MKGAY Merck KGaA
$0.00

(0.00%)

TEVA Teva
$23.47

0.39 (1.69%)

08/17/18
HCWC
08/17/18
NO CHANGE
Target $4.5
HCWC
Buy
H.C. Wainwright ups Antares price target to $4.50 after generic EpiPen approval
After the FDA announced the "long-awaited" approval of Antares Pharma (ATRS) and partner Teva's (TEVA) generic EpiPen, H.C. Wainwright analyst Oren Livnat said his estimates include nearly $40M in peak EpiPen revenue to Antares from the "biggest partnered pipeline opportunity" the company has modeled by his and consensus estimates. Livnat, who said he is not aware of any other substitutable EpiPen generics on the way, views the product as a sustainable contributor and raised his price target on Antares shares to $4.50 from $4.00 following the news. Livnat, who assumes Teva launches quickly after final label packaging, but believes that Teva "unfortunately" will miss the big EpiPen back-to-school prescribing season, keeps a Buy rating on Antares shares.
08/23/18
HCWC
08/23/18
NO CHANGE
Target $7
HCWC
Buy
Adamis selloff on generic EpiPen a buying opportunity, says H.C. Wainwright
Recent weakness in shares of Adamis Pharmaceuticals (ADMP) appears related to news that Teva (TEVA) has received approval to launch a generic version of Mylan's (MYL) EpiPen, H.C. Wainwright analyst Jason Kolbert tells investors in a research note. Sandoz, Adamis' partner, is well aware of Teva's initiatives and remains committed to the launch of Adamis' Symjepi, the analyst adds, As such, he views the recent pullback in Adamis as a buying opportunity. He lowered his price target for the stock to $7 from $10 and keeps a Buy rating on the name.
08/16/18
WELS
08/16/18
NO CHANGE
WELS
Market Perform
Teva's earlier than expected generic EpiPen bad news for Mylan, says Wells Fargo
Wells Fargo analyst David Maris said he believes the EpiPen generic seemed to have been thought of as a 2019 event by Mylan (MYL) and Teva (TEVA) investors, so the FDA approval today of the first generic EpiPen came earlier than expectations, which is both good news for Teva and negative news for Mylan. Mylan no longer breaks out the Specialty segment, so it is difficult to estimate how meaningful this is to the company, said Maris, but he believes "this is still an important product to Mylan." He keeps a Market Perform rating on Mylan shares, and for Teva calls the approval "a great addition for a company in need of good news."
08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,
RHHBY Roche
$0.00

(0.00%)

07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/28/18
08/28/18
UPGRADE
Target $4

Buy
Affimed N.V. upgraded to Buy after Roche collaboration at Jefferies
As previously reported, Jefferies analyst Maury Raycroft upgraded Affimed N.V. (AFMD) to Buy from Hold, stating that its collaboration with Roche Group's (RHHBY) Genentech to develop and commercialize novel NK cell engagers indicate the intrinsic value in Affimed's platform and approach. Affimed will retain its AFM13 and AFM11 wholly-owned clinical programs and can still partner with other companies, noted Raycroft, who raised his price target on Affimed shares to $4.00 from $1.80.

TODAY'S FREE FLY STORIES

CERS

Cerus

$5.35

-0.22 (-3.95%)

08:32
12/10/18
12/10
08:32
12/10/18
08:32
Hot Stocks
Cerus announces American Red Cross receives BLA approval for INTERCEPT platelets »

Cerus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDRX

Allscripts

$9.49

-0.01 (-0.11%)

08:32
12/10/18
12/10
08:32
12/10/18
08:32
Hot Stocks
GI Partners, TA Associates to acquire Allscripts' stake in Netsmart Technologies »

GI Partners together with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDRX

Allscripts

$9.49

-0.01 (-0.11%)

08:31
12/10/18
12/10
08:31
12/10/18
08:31
Hot Stocks
Breaking Hot Stocks news story on Allscripts »

GI Partners, TA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE/A

Forest City Enterprises Inc

$0.00

(0.00%)

, OVAS

OvaScience

$0.70

-0.0335 (-4.57%)

08:30
12/10/18
12/10
08:30
12/10/18
08:30
Options
One new option listing and three option delistings on December 10th »

New option listings for…

FCE/A

Forest City Enterprises Inc

$0.00

(0.00%)

OVAS

OvaScience

$0.70

-0.0335 (-4.57%)

SONC

Sonic

$43.48

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

XPER

Xperi

$12.80

-0.53 (-3.98%)

08:30
12/10/18
12/10
08:30
12/10/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Xperi »

Xperi Corp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

VERI

Veritone

$5.62

-0.09 (-1.58%)

08:28
12/10/18
12/10
08:28
12/10/18
08:28
Hot Stocks
Breaking Hot Stocks news story on Veritone »

Veritone up 45% to $8.16…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$106.35

-3.62 (-3.29%)

, EQIX

Equinix

$386.76

-6.1 (-1.55%)

08:28
12/10/18
12/10
08:28
12/10/18
08:28
Conference/Events
FBN Securities to hold a bus tour »

Silicon Valley Technology…

CHKP

Check Point

$106.35

-3.62 (-3.29%)

EQIX

Equinix

$386.76

-6.1 (-1.55%)

FTNT

Fortinet

$71.63

-3.79 (-5.03%)

ZS

Zscaler

$40.39

-2.61 (-6.07%)

FEYE

FireEye

$19.42

-0.78 (-3.86%)

FSCT

ForeScout

$25.83

-1.1 (-4.08%)

NTNX

Nutanix

$42.17

-2.23 (-5.02%)

SPLK

Splunk

$105.70

-5.43 (-4.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 12

    Dec

  • 13

    Dec

  • 17

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

  • 15

    Jan

AKAO

Achaogen

$1.40

-0.08 (-5.41%)

08:27
12/10/18
12/10
08:27
12/10/18
08:27
Hot Stocks
Achaogen receives FDA clearance for Thermo Scientific QMS Plazomicin Immunoassay »

Achaogen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$21.00

-0.69 (-3.18%)

08:26
12/10/18
12/10
08:26
12/10/18
08:26
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MGNX

MacroGenics

$16.44

-0.15 (-0.90%)

08:25
12/10/18
12/10
08:25
12/10/18
08:25
Recommendations
MacroGenics analyst commentary  »

MacroGenics hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

08:25
12/10/18
12/10
08:25
12/10/18
08:25
Conference/Events
Wolfe Research to hold a bus tour »

Wolfe Research…

IDCC

InterDigital

$72.10

-1.93 (-2.61%)

08:25
12/10/18
12/10
08:25
12/10/18
08:25
Conference/Events
InterDigital to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

XSPA

XpresSpa

$0.18

-0.0023 (-1.24%)

08:24
12/10/18
12/10
08:24
12/10/18
08:24
Hot Stocks
XpresSpa executes first franchise partnership »

XpresSpa announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$8.74

-0.155 (-1.74%)

, CRZBY

Commerzbank

$0.00

(0.00%)

08:23
12/10/18
12/10
08:23
12/10/18
08:23
Periodicals
German Finance Ministry open to merge Deutsche Bank, Commerzbank, Bloomberg says »

The German finance…

DB

Deutsche Bank

$8.74

-0.155 (-1.74%)

CRZBY

Commerzbank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPB

Campbell Soup

$37.76

-0.45 (-1.18%)

08:23
12/10/18
12/10
08:23
12/10/18
08:23
Periodicals
Ferrero 'interested' in Campbell's international unit, Reuters reports »

Ferrero, the maker of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$85.03

0.31 (0.37%)

08:22
12/10/18
12/10
08:22
12/10/18
08:22
Conference/Events
Guidewire management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

TSCO

Tractor Supply

$88.81

-3.57 (-3.86%)

08:21
12/10/18
12/10
08:21
12/10/18
08:21
Recommendations
Tractor Supply analyst commentary  »

Tractor Supply price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALE

Allete

$81.09

0.22 (0.27%)

08:21
12/10/18
12/10
08:21
12/10/18
08:21
Downgrade
Allete rating change  »

Allete downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Conference/Events
Jefferies to hold a tour »

North Carolina Healthcare…

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$137.42

-2.14 (-1.53%)

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Periodicals
Lynx Equity Strategies moves to 'Long bias' on Facebook »

Lynx Equity Strategies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$179.56

-7.3 (-3.91%)

08:20
12/10/18
12/10
08:20
12/10/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$64.56

-2.37 (-3.54%)

08:19
12/10/18
12/10
08:19
12/10/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.